Outlook Therapeutics inks $100 million at-the-market equity sales agreement with H.C. Wainwright

Outlook Therapeutics

Outlook Therapeutics

OTLK

0.00
  • Outlook Therapeutics entered an at-the-market offering agreement with H.C. Wainwright to sell up to USD 100 million of common stock.
  • H.C. Wainwright will act as sales agent or principal for sales on Nasdaq or in privately negotiated transactions at prevailing market prices.
  • Sales agent commission set at 3% of gross proceeds; company also agreed to reimburse certain legal fees.
  • Prior USD 100 million ATM program with BTIG was terminated effective May 12, 2026.
  • Cash and cash equivalents totaled about USD 7.7 million as of March 31, 2026, excluding USD 4.5 million of net proceeds from an April 2026 registered direct equity offering.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-060305), on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.